SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

ABEO

Abeona Therapeutics Inc.
MIXED
Impact 6/10
Horizonmonths Processed7d 17h ago WireGlobeNewswire
Press release · M&A
Actionable Insight ◆ Mixed

Watch for the planned Phase 3 trial design and enrollment update in mid-2027; the activist's next move (proxy contest or board negotiation) could surface in coming weeks. The PIPE's $3.75 price is at a ~15% discount to the current $4.41 market price, suggesting near-term overhang.

DirectionMixed
Confidencehigh
Horizonmonths

Drugs in focus

ABEO drug pipeline →

ABO-801

● Neutral Named in this press release
Impact
Phase
Phase 2 completed / Phase 3-ready
Time to market
ABO-801 is Phase 3-ready but no Phase 3 trial has been announced. Assuming a typical 1-2 year Phase 3 program plus FDA review, potential approval would be at least 3-4 years away, though the Fast Track designation could accelerate the timeline.
Next catalyst
None dated

What to watchWatch for the initiation of a Phase 3 trial for ABO-801 in eosinophilic esophagitis, which would be the next meaningful drug-specific catalyst. Near term, monitor the activist investor situation (James Russell's 6.1% stake and board-change demands) and the registration statement filing for the PIPE shares, as these could drive further volatility. The Q3 earnings beat and ZEVASKYN revenue growth ($13.5M, up 18% QoQ) provide a commercial foundation, but the dilutive financing and activist pressure create a mixed setup.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$2.54
T+0 close · Nov 9, 2026 · via day close
Latest settled
+2.36%
T+5 · $2.60
Vs SPY
+4.05%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $2.54entry
  2. T+1 · 7d ago −3.35%α −2.98% · $2.46
  3. T+5 · 17h ago +2.36%α +4.05% · $2.60
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Abeona Therapeutics acquires ABO-801 (formerly APT-1011), a Phase 3-ready oral therapy for eosinophilic esophagitis, from Ellodi Pharmaceuticals for $20M in stock with no upfront cash, plus up to $60M in milestones and tiered royalties. Concurrently, the company raises $30M in a PIPE financing at $3.75/share, with participation from leading life sciences investors. The deal diversifies Abeona's pipeline beyond its commercial gene therapy ZEVASKYN, but the PIPE dilutes existing holders by ~25% and the activist stake (6.1% from October 23) adds governance pressure.

Key Financial Metrics

Deal Value
$20.0M

Key Facts

  • Acquired ABO-801 (EoE candidate) from Ellodi for $20M in stock, no upfront cash; up to $30M FDA approval milestone, $30M sales milestones, and low-to-mid teen royalties.
  • ABO-801 has FDA Orphan Drug and Fast Track designations; two Phase 3 studies completed (neither met co-primary symptom endpoint, but showed histologic/endoscopic activity).
  • Planned Phase 3 study initiation mid-2027; topline results expected by end of 2028.
  • PIPE financing: $30M gross proceeds from 6.4M shares at $3.75/share and pre-funded warrants for 1.6M shares at $3.7499.
  • PIPE investors include Nantahala Capital, Marshall Wace, Monashee, Perceptive Advisors, TPG, and other healthcare funds.
  • Activist James Russell disclosed a 6.1% stake on October 23, requesting board changes and management review.
  • Proceeds will fund pipeline development and ZEVASKYN commercialization.

Financial Impact

PIPE adds $30M gross proceeds; acquisition consideration $20M in stock; total potential milestones up to $60M plus royalties. Dilution from PIPE: ~25% of pre-deal shares outstanding (6.4M shares + 1.6M pre-funded warrants vs. ~25M pre-deal shares).

dilutioncashpipeline value

Risk Factors

  • ABO-801's prior Phase 3 failures on the symptom endpoint increase regulatory risk; the new Phase 3 may not succeed.
  • PIPE dilution (~25%) pressures existing holders; activist may push for further changes or a sale.
  • Commercial execution of ZEVASKYN remains unproven; cash burn may accelerate without near-term revenue.
  • Ellodi's milestone/royalty obligations add future cost if ABO-801 succeeds.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398196

Track record

29 reports on ABEO

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $2.59 Now $2.60 +0.39% settles Nov 18
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
  3. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
  4. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
  5. Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
  6. Nov 9, 20267d ago Press Release Mixed 6/10 Viewing Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
  7. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
  8. Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
  9. Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
  10. Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 9h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026